Skip to main content

Table 2 Respondents preferences for colorectal cancer screening

From: Public stated preferences and predicted uptake for genome-based colorectal cancer screening

Attribute level

β − coefficient

95% CI

Preparation

  

  No preparation

0.38 (0.02)a

0.34 to 0.42

  Laxatives

−0.03 (0.01)b

−0.06 to -0.01

  Enemas

−0.16 (0.01)a

−0.19 to -0.13

  Diet plus laxatives#

−0.19 (0.02)a

−0.22 to -0.16

Technique

  

  Pill

0.48 (0.02)a

0.44 to 0.52

  Stool

0.24 (0.02)a

0.20 to 0.28

  Long tube with sedation#

−0.34 (0.02)a

−0.39 to -0.30

  Short tube

−0.37 (0.02)a

−0.41 to -0.33

Sensitivity

  

  100%

0.36 (0.02)a

0.32 to 0.39

  90%

0.08 (0.01)a

0.05 to 0.10

  80%

−0.14 (0.01)a

−0.17 to -0.11

  70%#

−0.30 (0.02)a

−0.33 to -0.26

Specificity

  

  100%

0.15 (0.01)a

0.12 to 0.17

  90%

0.06 (0.01)a

0.03 to 0.09

  80%

−0.04 (0.01)a

−0.07 to -0.02

  70%#

−0.16 (0.02)a

−0.19 to -0.13

Complications

  

  None

0.14 (0.02)a

0.11 to 0.17

  1/10.000

0.04 (0.01)a

0.01 to 0.06

  10/10.000

−0.04 (0.01)a

−0.07 to 0.02

  100/10.000#

−0.13 (0.02)a

−0.16 to -0.10

Frequency

  

  Biennial

0.17 (0.02)a

0.14 to 0.21

  Annual#

0.03 (0.02)

−0.01 to 0.07

  Every 5 years

0.01 (0.02)

−0.03 to 0.04

  Every 10 years

−0.21 (0.02)a

−0.26 to -0.17

No screening

−0.29 (0.03)a

−0.36 to -0.23

  1. #: reference level in effects coding; ap-value < 0.005; bp-value < 0.05; 65079 Observations, 1356 respondents. McFadden R2 = 11.0%.